Monte Rosa Therapeutics Stock News

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of Jullian Jones, Ph.D., J.D., MBA, to Chief Business Officer. Dr. Jones, who previously served as Senior Vice President, Head of Business Development, has over a decade of experience directing development and partnership transactions within the life sciences industry.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) gapped up prior to trading on Friday . The stock had previously closed at $17.99, but opened at $18.68. Monte Rosa Therapeutics shares last traded at $18.33, with a volume of 643 shares trading hands. A number of equities research analysts recently commented on GLUE shares. Zacks Investment Research cut []

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $17.24 and last traded at $17.99, with a volume of 144109 shares changing hands. The stock had previously closed at $18.57. Several brokerages have issued reports on GLUE. Zacks Investment Research […]

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has earned an average recommendation of Buy from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month []

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its man

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The company’s pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2.

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) gapped down before the market opened on Thursday . The stock had previously closed at $21.94, but opened at $21.30. Monte Rosa Therapeutics shares last traded at $21.50, with a volume of 344 shares traded. Several brokerages have issued reports on GLUE. SVB Leerink began coverage on shares []

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been given a consensus recommendation of Buy by the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The []

Zacks Investment Research lowered shares of Monte Rosa Therapeutics (NASDAQ:GLUE) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports. According to Zacks, Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the bodys natural []

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)s stock price traded up 5.1% on Monday . The stock traded as high as $26.47 and last traded at $26.47. 39 shares changed hands during trading, a decline of 100% from the average session volume of 213,007 shares. The stock had previously closed at $25.19. Several analysts recently weighed in []

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)s share price dropped 7.4% on Tuesday . The stock traded as low as $21.28 and last traded at $21.29. Approximately 2,700 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 211,790 shares. The stock had previously closed at $23.00. GLUE has been the []

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical d

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be ad

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmut